Adalimumab Monotherapy in a Patient with Psoriatic Arthritis Associated with Chronic Renal Failure on Hemodialysis: A Case Report and Literature Review

Yasuhiro Shimojima; Masayuki Matsuda; Wataru Ishii; Shu-ichi Ikeda

doi:10.4137/CCRep.S8790

Clinical Medicine Insights: Case Reports (Jan 2012)

Adalimumab Monotherapy in a Patient with Psoriatic Arthritis Associated with Chronic Renal Failure on Hemodialysis: A Case Report and Literature Review

Yasuhiro Shimojima,
Masayuki Matsuda,
Wataru Ishii,
Shu-ichi Ikeda

Affiliations

Yasuhiro Shimojima: Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
Masayuki Matsuda: Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
Wataru Ishii: Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
Shu-ichi Ikeda: Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.

DOI: https://doi.org/10.4137/CCRep.S8790
Journal volume & issue: Vol. 5

Abstract

Read online

We report a patient with psoriatic arthritis (PsA) who was successfully treated with adalimumab even while under hemodialysis therapy for associated chronic renal failure. Flow cytometry of circulating lymphocytes revealed an obvious decrease in both Th1 and Th17 cells after starting adalimumab. The latter returned to the pretreatment level in the course of adalimumab therapy, while the former did not. Adalimumab is a potent therapeutic option for PsA patients with chronic renal failure on hemodialysis, and Th1 in peripheral blood may reflect the disease activity.

Published in Clinical Medicine Insights: Case Reports

ISSN: 1179-5476 (Online)
Publisher: SAGE Publishing
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General)
Website: https://journals.sagepub.com/home/icr

About the journal